Janus Henderson Group plc Ordinary Shares (JHG)
Janus Henderson Group plc is a global asset management company offering a wide range of investment strategies across equities, fixed income, and alternative assets. Founded through a merger between Janus Capital Group and Henderson Group in 2017, it serves individual and institutional clients worldwide, emphasizing active management and research-driven investment approaches.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 28, 2025 | $0.40 | 2025-08-11 | 2025-08-11 |
| May 29, 2025 | $0.40 | 2025-05-12 | 2025-05-12 |
| February 27, 2025 | $0.39 | 2025-02-11 | 2025-02-11 |
| November 27, 2024 | $0.39 | 2024-11-08 | 2024-11-11 |
| August 28, 2024 | $0.39 | 2024-08-12 | 2024-08-12 |
Dividends Summary
- Janus Henderson Group plc Ordinary Shares has issued 33 dividend payments over the past 8 years
- The most recent dividend was paid 55 days ago, on August 28, 2025
- The highest dividend payed out to investors during this period was $0.40 per share
- The average dividend paid during this period was $0.37 per share.
Company News
American Express partners with RewardPay to enable New Zealand businesses to pay taxes via credit card and earn reward points, enhancing B2B fintech capabilities and providing businesses with flexible payment options.
Goldman Sachs expects macro uncertainty, rate cuts, and weak equity markets to weigh on earnings for capital markets firms, with alternative managers facing heightened risks and brokers/wealth advisors seeing mixed results. Brookfield Asset Management is highlighted as a standout.
KBW, a subsidiary of Stifel Financial, announced changes to four of its indexes for Q4 2024, including additions and removals of various financial services and fintech companies.
Janus Henderson Group PLC and its associated fund have significantly increased their holdings in ARCA biopharma, Inc., a biotech company, by purchasing shares worth approximately $1.43 million. The investment highlights Janus Henderson's belief in the long-term potential of ARCA biopharma.
